New immunotherapy combo aims to fight advanced kidney cancer
NCT ID NCT07159191
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a combination of two drugs—envafolimab (an immunotherapy injection) and axitinib (a targeted therapy pill)—as a first treatment for people with advanced kidney cancer that has spread or cannot be removed. About 30 participants will receive the treatment for up to 2 years. Researchers will measure how well the drugs shrink tumors and control the cancer, while closely monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Envafolimab (immunotherapy injection) and Axitinib (targeted therapy pill)
What this could lead to
If successful, this combination could offer a new first-line treatment option for advanced kidney cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong
This is a small, early-phase (Phase 2) study with only 30 participants and no comparison group. The treatment may cause side effects like immune reactions or high blood pressure, and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED RENAL CELL CARCINOMA (ARCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••